Investor Presentation
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Akums delivered a strong FY26 performance with total income of Rs 4,488 crore (up 7.6% YoY) and adjusted EBITDA of Rs 522 crore (up 13.3% YoY), recovering from a challenging H1 FY26 marked by API price erosion and muted domestic volumes. Q4 FY26 revenue stood at Rs 1,158 crore with adjusted EBITDA of Rs 152 crore (13.1% margin), showing sequential improvement. CDMO business drove growth with double-digit volume increases despite industry headwinds. Key milestones include the 200 million Euro multi-year European CDMO contract progressing on schedule (supplies from FY28), first EU dossier approval received, EU GMP certification for Plant 2, and a JV with the Zambian government committing USD 25 million per year in supplies for FY27-28. Capacity utilization improved to 44% with new facilities ramping up. However, API segment losses persisted while Trade Generics turned EBITDA positive in Q4.
The company demonstrates strong recovery trajectory and expanding margins driven by CDMO momentum and better product mix. The multi-year European contract and Zambia JV provide revenue visibility through FY28 and beyond, though API headwinds and rising finance costs (up 172% YoY to Rs 94 crore) remain watch items.